RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.com
"Most Common Oral Lesions" Presentation at Trimira.net Created by Dental Textbook Author Dr. Jerry Bouquot – Trimira Presentation Spotlights Identafi "Multispectral" Technology
HOUSTON, Oct. 15, 2009 — Prolific author and professor Dr. Jerry Bouquot, DDS, MSD, of Houston, has created a new presentation titled "The 53 Most Common Oral Lesions" at www.Trimira.net. It is illustrated with images from Trimira® LLC's online catalogue of clinical photographs taken by leading scientists and researchers.
Clinical Image Library Available to Registered Users
Bouquot is a co-author of the dental textbook "Oral and Maxillofacial Pathology" (http://tinyurl.com/ylq9nxw), 3rd edition, with co-authors Brad Neville DDS, Douglas D. Damm DDS, and Carl M. Allen DDS MSD. This textbook is the oral pathology bible for dental schools around the world. Bouquot is a professor and chair of the Department of Diagnostic Sciences at The University of Texas' Dental Branch at Houston.
Dr. Bouquot
www.db.uth.tmc.edu/research/Faculty_Prof/Bouquot_Jerry_FacultyProfile.html
Bouquot also is an adjunct professor at Rural Health & Community Dentistry, School of Dentistry, West Virginia University; a consultant in oral pathology at the Department of Pathology, New York Eye & Ear Infirmary, New York City; and a consultant in pediatric oral pathology at the Division of Dentistry, Pittsburgh Children's Hospital.
Bouquot's presentation highlights the quality and range of intraoral images available at www.Trimira.net to dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians. The library is accessible to registered users, while a simplified, sample version is accessible to nonregistered healthcare professionals. The online catalogue is the first version of what is expected to become an invaluable practitioner resource. A more comprehensive online version 2.0 will go live in coming months.
Identafi Is Only Device to Use "Multispectral" Technology
As a clinical reference tool (online at www.trimira.net/clinical-images) Trimira®'s online image library is organized into four main detection areas: the tongue, floor of mouth, buccal mucosa, and palate. The images are categorized by location in the mouth, type of dysplasia, and appearance under each of Trimira®'s three proprietary Identafi® 3000 ultra "multispectral" wavelengths: brilliant white, violet, and green-amber light.
Within each category the images feature normal male and female tissue samples along with several series of different dysplastic oral tissue, including invasive cancer delineated by each of the multispectral wavelengths. Users can log-on and see exactly what lesions look like under Identafi® 3000 ultra’s brilliant white, violet, and green-amber illumination. This tool delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care.
Created exclusively for intraoral use, the small, cordless Identafi® 3000 ultra unit is ergonomically shaped for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians. The industry-leading device incorporates next-generation oral cancer-detection optical reflectance and fluorescence technology, which is changing the screening and diagnostic landscape for the nation's dentists and doctors.
Identafi® 3000
Identafi® 3000 ultra's multispectral spectroscopy minimizes false positives and reveals abnormalities in oral tissue missed by the naked eye. Unlike other methods, Identafi® 3000 ultra empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. It represents a quantum leap in the visualization of oral cancer or premalignant dysplasia. Multispectral technology not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers.
About Trimira® LLC
Trimira® LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm®, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm®'s core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira® at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
